You are viewing: Mexico AI in Biotechnology Market analysis
Part of: AI in Biotechnology Market (Global)

The Mexico AI in Biotechnology Market was valued at $63.9 Million in 2030 and projected to reach to $142.3 Million by 2035, representing a compound annual growth rate of 17.5%. Mexico's AI in biotechnology market is poised for significant expansion through 2035, driven by increasing healthcare investments, growing pharmaceutical R&D activities, and rising adoption of AI technologies in drug development.

Mexico AI in Biotechnology Market (2030-2035) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Mexico AI in Biotechnology Market Trends and Insights

  • This 17.5% compound annual growth rate reflects Mexico's increasing adoption of artificial intelligence technologies across drug discovery, genomics, and personalized medicine applications.
  • Mexico is positioning itself as a regional hub for biotech innovation, driven by government initiatives, rising healthcare investments, and growing collaboration between academic institutions and private sector players. The Mexican biotechnology sector is leveraging AI to accelerate research timelines and reduce development costs, particularly in pharmaceutical and diagnostic applications.
  • Between 2030 and 2035, Mexico's market is expected to more than double, supported by enhanced digital infrastructure and talent development in computational biology.
  • Mexico's strategic location and proximity to North American markets further strengthen its competitive advantage in the AI-driven biotechnology landscape..

Key Market Statistics

  • CAGR (2030-2035) 17.5% CAGR
  • Market Size, 2030 ~USD 63.9 Million
  • Forecast, 2035 ~USD 142.3 Million
  • Country Mexico

Mexico AI in Biotechnology Market Overview

Market Valuation Growth :

Mexico's AI in biotechnology market is valued at $63.9 million in 2030 and is projected to expand to $142.3 million by 2035, representing a 122% increase over five years.

Strong CAGR Performance :

Mexico's market is growing at a 17.5% CAGR from 2030-2035, slightly below the global average of 18.5%, indicating steady regional adoption and competitive positioning in Latin America.

Key Application Areas :

Mexico's AI biotechnology adoption is concentrated in drug discovery, genomics analysis, and personalized medicine, reflecting the country's focus on precision healthcare solutions and pharmaceutical innovation.

Regional Hub Development :

Mexico is establishing itself as a regional biotechnology hub in Latin America, leveraging proximity to North American markets, growing research infrastructure, and increasing investment in AI-driven biotech capabilities.

Mexico AI in Biotechnology Market Dynamics

  • The country's strategic location and emerging biotech ecosystem are attracting both domestic and international players seeking to leverage AI for accelerated drug discovery and genomic research. Government initiatives supporting healthcare innovation, coupled with partnerships between Mexican research institutions and global biotech firms, are expected to accelerate market growth.
  • The convergence of AI capabilities with Mexico's existing pharmaceutical manufacturing base creates unique opportunities for personalized medicine development and precision diagnostics, positioning the nation as a competitive player in the Latin American biotech landscape..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • Mexico's AI in biotechnology market will grow from $63.9M (2030) to $142.3M (2035) at a 17.5% CAGR.
      • Mexico is emerging as a regional innovation hub with increasing government support and private sector investment in AI-biotech applications.
      • Drug discovery, genomics, and personalized medicine are primary growth drivers in Mexico's AI biotechnology sector.
      • Mexico's geographic proximity to North American markets and developing digital infrastructure position it for accelerated market expansion through 2035.

      AI in Biotechnology Market Report Scope

      Report Metric Details
      Base Year 2030
      Fastest Growing Segment DRUG DISCOVERY (Type)
      Forecast Period 2030–2035
      Growth Rate CAGR of 18.5% from 2030 to 2035
      Largest Segment CLOUD-BASED SOLUTIONS (Deployment Mode)
      Market Size Base Year (Billions) ~USD 9.72 (2030)
      Revenue Forecast (Billions) ~USD 22.72 (2035)
      Segments Covered Offering, Function, Type, Deployment Mode, End User

      Mexico AI in Biotechnology Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Offering

      • End-To-End Solutions
      • Niche Solutions
      • Services
      • Technologies
      • Technology

      By Function

      • Corporate
      • Launch & Commercial
      • Manufacturing & Supply Chain
      • Post-Marketing Surveillance & Patient Support
      • Regulatory Compliance
      • Research & Development

      By Type

      • Adverse Event Reporting
      • Biomarker Discovery
      • Clinical Data Assessment
      • Clinical Development
      • Compliance Monitoring
      • Consulting Services
      • Demand Forecasting
      • Drug Discovery
      • Hybrid Cloud
      • Implementation Services & Ongoing It Support
      • Inventory Management
      • Launch Coordination
      • Logistics Optimization
      • Marketing Operations
      • Medication Adherence
      • Molecular Design & Optimization
      • Monitoring & Drug Adherence
      • Multi Cloud
      • Other Corporate Functions
      • Other Manufacturing & Supply Chain Functions
      • Patient Engagement
      • Patient Monitoring
      • Patient Support Programs
      • Post-Sales & Maintenance Services
      • Predictive Maintenance
      • Predictive Pricing
      • Predictive Toxicity & Risk Monitoring
      • Private Cloud
      • Public Cloud
      • Real-World Evidence (Rwe) Analysis
      • Real-World Evidence(Rwe) Analysis
      • Recruitment
      • Risk Management
      • Sales Force Optimization
      • Site Selection
      • Structure-Activity Relationship (Sar) Modeling
      • Supply Chain Planning
      • Training & Education Services
      • Trial Design

      By Deployment Mode

      • Cloud-Based Solutions
      • On-Premises Solutions

      By End User

      • Biotechnology Companies
      • Clinical Research Organizations
      • Contract Research Organizations
      • Healthcare Providers
      • Pharmaceutical Companies
      • Research Institutes & Labs

      Target Audience

      • Pharmaceutical Companies : Mexican and international pharma firms need market intelligence to optimize R&D investments, accelerate drug discovery timelines, and leverage AI capabilities for competitive advantage in the regional market.
      • Biotech Startups & Entrepreneurs : Emerging biotech ventures in Mexico require detailed market data to secure funding, identify partnership opportunities, and understand growth potential in AI-driven drug development and genomics applications.
      • Healthcare Investors & VCs : Investment firms targeting Mexico's biotech sector need comprehensive market analysis to identify high-potential companies, assess market growth trajectories, and make informed capital allocation decisions.
      • Research Institutions & Universities : Mexican academic and research organizations need market insights to align research initiatives with commercial opportunities, attract funding, and establish collaborations with industry players in AI biotechnology.
      • Healthcare Policy Makers : Government agencies and regulatory bodies in Mexico require market data to develop supportive policies, allocate resources for biotech innovation, and position Mexico as a competitive regional biotech hub.

      Key Companies in the Mexico AI in Biotechnology Market

      CompanyHQOwnershipStrongest segments
      NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI Compute & Networking,Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Arrays and genotyping consumables,
      RECURSIONUnited StatesPublic CompanyPlatform collaboration and milestones,Internal pipeline R&D funding (capitalized/other income),Other services and data partnerships,
      SCHRöDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations (e.g., Novartis and others),Drug Discovery – Internal Pipeline,
      BENEVOLENTAIUnited KingdomPrivate CompanyAI discovery platform and licenses,Collaborative R&D projects and services,Custom data/ontology and analytics solutions,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health, transplant, viral load),PCR and digital PCR instruments and consumables,
      TEMPUSUnited StatesPublic CompanyOncology NGS diagnostics (xT, xR, solid tumor and hematologic panels),Other diagnostics (PCR profiling, pathology, inherited conditions, pharmacogenomics nP),Data licensing and software (Insights, Lens, Hub, Next, Algos, Organoids, Trials),
      SOPHIA GENETICSSwitzerlandPublic CompanySOPHiA DDM platform subscriptions and usage-based analytics,Implementation, support, and workflow services,Biopharma collaborations and data-driven research solutions,
      PREDICTIVE ONCOLOGYUnited StatesPublic CompanyCompute Services and Treasury Management,Drug Discovery Services,
      XTALPI INC.ChinaPublic CompanyAI-driven drug discovery solutions (hit discovery, optimization, biology, PepiX),Computational software platforms (XFEP, XMolGen, PatSight, XtalGazer),Automation hardware and integrated workstations (XmartChem, ChemPlus),

      NVIDIA CORPORATION

      NVIDIA Corporation is a publicly traded technology company founded in 1993 and headquartered in the United States. With 42,000 employees, the company designs and manufactures graphics processing units and system-on-chip units. NVIDIA serves markets including gaming, professional visualization, data centers, and artificial intelligence.

      ILLUMINA, INC.

      Illumina, Inc. is a publicly traded genomics company founded in 1998 and based in the United States. The company employs 8,625 people and specializes in DNA sequencing and array-based technologies. Illumina's platforms are used for applications in research, clinical diagnostics, and precision medicine.

      RECURSION

      Recursion is a publicly traded biotechnology company founded in 2013 and headquartered in the United States. With 600 employees, the company uses machine learning and high-throughput biology to discover and develop therapeutics. Recursion focuses on identifying novel drug candidates through computational and experimental approaches.

      SCHRöDINGER, INC.

      Schrödinger, Inc. is a publicly traded computational chemistry and drug discovery company founded in 1990 and based in the United States. The company employs 850 people and develops software platforms for molecular simulation and drug design. Schrödinger's tools are used by pharmaceutical and biotechnology companies to accelerate drug development.

      BENEVOLENTAI

      BenevolentAI is a privately held artificial intelligence company founded in 2013 and headquartered in the United Kingdom. With 173 employees, the company applies machine learning and AI to drug discovery and development. BenevolentAI focuses on identifying new therapeutic targets and repurposing existing drugs for various diseases.

      QIAGEN

      QIAGEN is a publicly traded life sciences company founded in 1984 and headquartered in the Netherlands. With 5,500 employees, the company develops and manufactures sample preparation and molecular testing technologies. QIAGEN serves customers in molecular diagnostics, applied testing, and academic research.

      TEMPUS

      Tempus is a publicly traded artificial intelligence and precision medicine company founded in 2015 and based in the United States. With 3,800 employees, the company leverages machine learning and data analytics to improve cancer treatment and outcomes. Tempus analyzes clinical and molecular data to provide actionable insights for oncology care.

      SOPHIA GENETICS

      Sophia Genetics is a publicly traded digital health company founded in 2011 and headquartered in Switzerland. With 415 employees, the company develops AI-powered platforms for genomic data interpretation and clinical decision support. Sophia Genetics serves hospitals, diagnostic laboratories, and research institutions globally.

      PREDICTIVE ONCOLOGY

      Predictive Oncology is a publicly traded cancer diagnostics and treatment company founded in 2002 and based in the United States. With 14 employees, the company develops personalized medicine solutions for oncology patients. Predictive Oncology focuses on tumor profiling and treatment prediction technologies.

      XTALPI INC.

      XtalPi Inc. is a publicly traded artificial intelligence and drug discovery company founded in 2015 and headquartered in China. The company uses machine learning and computational chemistry to accelerate drug discovery and development. XtalPi focuses on molecular simulation and structure-based drug design.

      Reasons to Buy this Report

      • Market Entry Strategy : Gain detailed insights into Mexico's AI biotechnology landscape to develop targeted market entry strategies, identify key stakeholders, and understand regulatory pathways specific to the Mexican biotech sector.
      • Investment Opportunity Assessment : Evaluate investment potential in Mexico's high-growth AI biotech market with 17.5% CAGR, identifying emerging companies, funding trends, and partnership opportunities in drug discovery and genomics.
      • Competitive Positioning : Benchmark your organization against competitors in Mexico's AI biotechnology space, understand market dynamics, and identify gaps in service offerings for personalized medicine and genomic analysis.
      • Regional Expansion Planning : Leverage Mexico-specific data to expand operations across Latin America, utilizing Mexico as a regional hub for AI biotech innovation and establishing distribution networks for precision medicine solutions.
      • Technology Adoption Insights : Understand adoption rates of AI technologies in Mexican pharmaceutical companies, research institutions, and healthcare providers to tailor product development and marketing strategies for maximum market penetration.

      Frequently asked questions

      What is the current size of Mexico's AI in biotechnology market?

      Mexico's AI in biotechnology market was valued at $63.9 million in 2030 and is projected to reach $142.3 million by 2035.

      What is the growth rate for AI in biotechnology in Mexico?

      Mexico's AI in biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 17.5% from 2030 to 2035.

      Which applications are driving AI adoption in Mexico's biotechnology sector?

      Key applications include drug discovery acceleration, genomic analysis, personalized medicine development, and diagnostic innovation across Mexico's biotech ecosystem.

      What factors are supporting Mexico's AI biotechnology market growth?

      Growth is driven by government initiatives, increased healthcare investments, academic-industry collaboration, improved digital infrastructure, and Mexico's strategic regional position.

      How does Mexico's market compare to the global AI in biotechnology trend?

      Mexico's 17.5% CAGR is competitive with the global average of 18.5%, demonstrating Mexico's strong alignment with worldwide AI biotechnology adoption trends.

      RESEARCH METHODOLOGY

      This market research study primarily relied on secondary sources, directories, and databases to collect information for this technical, market-oriented, and financial analysis of the AI in biotechnology market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants, among others, to gather and verify critical qualitative and quantitative data and assess market prospects. The size of the AI in biotechnology market was estimated using multiple secondary research methods and confirmed with inputs from primary research to determine the final market size.

      Secondary Research

      The secondary research process involved extensively using secondary sources, including directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), Healthcare Information and Management Systems Society (HIMSS), Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, expert interviews, and MarketsandMarkets analysis.

      Secondary research was conducted to gather information for the detailed, technical, market-focused, and commercial analysis of the AI in biotechnology market. It was also used to collect key information about major players, market classification, and segmentation based on industry trends, down to the most detailed level, along with significant developments related to market and technology perspectives. Additionally, a database of leading industry players was compiled using secondary research.

      Primary Research

      During the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources mainly include industry experts from core and related industries, preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations involved in all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, among other specialists, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, and strategies adopted by key players.

      After completing the market engineering process- which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation- extensive primary research was carried out. This research aimed to gather information and verify the key numbers obtained during the market analysis. Additionally, primary research was used to identify different types of market segmentation, analyze industry trends, evaluate the competitive landscape of AI solutions for biotechnology offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market players.

      In the complete market engineering process, the top-down and bottom-up approaches, along with several data triangulation methods, were extensively used to estimate and forecast the market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted on the entire market engineering process to identify key information and insights throughout the report.

      Breakdown of Primary Interviews

      AI in Biotechnology Market

      Note 1: Others include sales, marketing, and product managers.

      Note 2: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The market size estimates and forecasts in this study are based on a combination of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (evaluation of utilization, adoption, and penetration trends by offering, function, deployment mode, end user, and region).

      AI in Biotechnology Market

      Data Triangulation

      After determining the overall market size from the estimation process described above, the market for AI in biotechnology was divided into various segments and subsegments. To finalize the overall market analysis and obtain accurate statistics for all segments and subsegments, data triangulation and market breakdown techniques were used whenever applicable. The data was cross-verified by examining different factors and trends from both the demand and supply sides of the market for AI in biotechnology.

      Market Definition

      The AI in biotechnology market includes technologies that use artificial intelligence to advance drug discovery, genomics, and personalized medicine. This market is defined by the growing utilization of machine learning and data analytics to improve research and development efficiency.

      Stakeholders

      • Healthcare IT service providers
      • Pharmaceutical/Biopharmaceutical companies
      • Biotechnology firms
      • AI technology providers
      • Academic & research institutions
      • Academic medical centers/universities/hospitals
      • Regulatory agencies
      • Clinical research organizations (CROs)
      • Genomic testing labs
      • Government agencies
      • Startups in AI and biotech
      • Pharmaceutical supply chain partners
      • Consulting firms
      • Clinical trial management system providers
      • Bioinformatics companies
      • Advocacy groups
      • Investors & financial institutions

      Report Objectives

      • To define, describe, and forecast the AI in biotechnology market by offering, function, deployment mode, end user, and region
      • To provide detailed information regarding the major drivers, restraints, opportunities, and challenges influencing market growth
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in biotechnology market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the AI in biotechnology market in five main regions (and their respective countries): North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To provide key industry insights, such as value chain, regulatory, patent, and recession impact analysis
      • To profile the key players in the market and comprehensively analyze their core competencies
      • To track and analyze competitive developments, such as product launches & upgrades, collaborations, partnerships, acquisitions, investments, contracts, agreements, alliances, mergers, funding, and expansions of the leading players in the market
      • To benchmark players within the market using the company evaluation matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

      Get the Full AI in Biotechnology Market Report

      Full forecast, segment splits, and company analysis for all AI in Biotechnology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status